Sanofi (SAN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Vétoquinol SA

OSE Immunotherapeutics SA

Ipsen SA

Sanofi

DBV Technologies SA

Genfit SA

Sensorion SA

Cellectis SA

MedinCell SA

Innate Pharma SA

PHAXIAM Therapeutics SA

Why is Sanofi ?

Poor Management Efficiency with a low ROCE of 11.13%

The company has been able to generate a Return on Capital Employed (avg) of 11.13% signifying low profitability per unit of total capital (equity and debt)

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 19.70

Poor long term growth as Net Sales has grown by an annual rate of 1.85% and Operating profit at 7.70% over the last 5 years

Flat results in Jun 25

INVENTORY TURNOVER RATIO(HY) Lowest at 1.36%

With ROE of 10.62%, it has a Attractive valuation with a 1.49 Price to Book Value

Over the past year, while the stock has generated a return of -8.13%, its profits have risen by 14.5% ; the PEG ratio of the company is 0.8

Underperformed the market in the last 1 year

Even though the market (France CAC 40) has generated returns of 8.73% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -8.13% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Sanofi should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Sanofi for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

Sanofi

-8.13%

-0.34

25.13%

France CAC 40

8.73%

0.52

16.76%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1.85%

EBIT Growth (5y)

7.70%

EBIT to Interest (avg)

19.70

Debt to EBITDA (avg)

0.68

Net Debt to Equity (avg)

0.11

Sales to Capital Employed (avg)

0.45

Tax Ratio

17.98%

Dividend Payout Ratio

88.23%

Pledged Shares

Institutional Holding

0.07%

ROCE (avg)

11.13%

ROE (avg)

12.55%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.49

EV to EBIT

11.09

EV to EBITDA

7.92

EV to Capital Employed

1.46

EV to Sales

2.76

PEG Ratio

0.80

Dividend Yield

4.63%

ROCE (Latest)

13.12%

ROE (Latest)

10.62%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

Bearish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

INTEREST COVERAGE RATIO(Q)

Highest at 3,142.13

RAW MATERIAL COST(Y)

Fallen by -4.96% (YoY

CASH AND EQV(HY)

Highest at EUR 15,359 MM

DEBT-EQUITY RATIO (HY)

Lowest at 9.89 %

EPS(Q)

Highest at EUR 4.72

-1What is not working for the Company

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.36%

Here's what is working for Sanofi

Interest Coverage Ratio

Highest at 3,142.13

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

EPS

Highest at EUR 4.72

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (EUR)

Cash and Eqv

Highest at EUR 15,359 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at 9.89 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -4.96% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sanofi

Inventory Turnover Ratio

Lowest at 1.36%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio